Pharmacogenetics and smoking cessation with nicotine replacement therapy.
Nicotine replacement therapies (NRTs), including transdermal patch, gum, lozenge, nasal spray and inhaler, are widely used for the treatment of tobacco dependence; however, only one-quarter to one-third of smokers who utilise NRTs to quit smoking are able to maintain long-term abstinence from tobacco use. Pharmacogenetic studies of NRT may be useful to identify subgroups of smokers who respond more favourably to specific NRTs, and to determine the optimal dose and duration of NRT. To date, pharmacogenetic studies have examined genes coding for nicotine metabolising enzymes, as well as proteins in neurotransmitter pathways that mediate the effects of nicotine. Initial findings suggest that polymorphisms in nicotine metabolising enzymes, and selected genes in the dopaminergic and opioidergic pathways, may have predictive validity for NRT response; however, independent replication is necessary before translation to clinical practice. Larger-scale investigations that incorporate pathway-based or genome-wide analysis, as well as intermediate measures of nicotine dependence (i.e. 'endophenotypes'), may be necessary to capture the complexity of pharmacogenetic effects.
Ray
Riju
R
Department of Psychiatry, The Transdisciplinary Tobacco Use Research Center and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
Schnoll
Robert A
RA
Lerman
Caryn
C
D006801:Humans; D009538:Nicotine / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D018722:Nicotinic Agonists / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D016032:Randomized Controlled Trials as Topic; D012907:Smoking / Q000235:genetics; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention
D018722:Nicotinic Agonists; D009538:Nicotine